| A global multicenter，randomized，double-blind，placebo -controlled， adaptive designed phase Ⅲ clinical trial to evaluate the efficacy， safety and immunogenicity of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old and above |
Rejected |
Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) |
3 |
CS-CTP-AD5NCOV-ⅢCo |
King Fahad Medical City (Riyadh) |
| A phase III randomized clinical trial comparing post-transplant cyclophosphamide with calcineurin inhibitors as a GVHD prophylaxis to standard care of methotrexate and calcineurin inhibitors for acute leukemia incorporating patient pharmacogenomic profiling – a personalized medicine approach in allogeneic hematopoietic cell transplantation PMAT |
Ongoing |
CYCLOPHOSPHAMIDE (ENDOXAN) |
3 |
1- 28/05/2019 |
KFSH & RC-R |
| Phase 2, Multi-Center, Double-Blind, Randomized, 2-Arm, Parallel Study to Assess the Efficacy and Safety of Ryanodex (EGL-4104) as Adjuvant Treatment in Subjects with Exertional Heat Stroke (EHS) |
Ongoing |
Dantrolene |
2 |
EGL-4104-C-1801 |
Mina Al-Shari' Al-Jadid Hospital |
| An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents from 5 to less than 18 Years of Age with Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC) |
Rejected |
Mirabegron |
3 |
178-CL-206A |
King Abdulaziz University Hospital (Jeddah) |
| Vitamin D Status Correction and Validation of its Potential Clinical Utility through Discovery Proteomic Analysis |
Completed |
cholecalciferol |
3 |
E-15-1667 |
KKUH |
| Vitamin D status and Covid-19 in Saudi Settings: A randomized open-label study on the possible role of vitamin D on improving clinical outcomes |
Ongoing |
VITA-D |
3 |
H-01-R-012 |
King Fahad Medical City (Riyadh) |
| Vitamin C as a potential ameliorating agent against hepatotoxicity among alcoholic abusers |
Completed |
Vitamin C (ascorbic acid ) Cevital |
3 |
20111803 |
Mental Health Hospital (Abha) |
| V212-001 A Phase III Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Efficacy of V212 in Adult Patients With Solid Tumor or Hematologic Malignancy |
Completed |
V212 |
3 |
V212-011 |
KFSH |
| Treatment of Neuroendocrine Tumors (NETs) with combination of Everolimus and Radiolabeld Somatostatin Analogue" |
Ongoing |
Everolimus |
2 |
ONC-CRC 12- 12 or (RAC # 2121 159) |
KFSH & RC-R |
| "Tranexamic acid for the treatment of significant traumatic brain injury: an international randomised, double blind placebo controlled trial" |
Ongoing |
(Cyklokapron) Tranexamic Acid |
3 |
ISRCTN15088122 |
KSMC |
